In the latest trading session,, 0.49 million Coherus Oncology Inc (NASDAQ:CHRS) shares changed hands as the company’s beta touched 0.89. With the company’s most recent per share price at $0.89 changing hands around $0.06 or 7.69% at last look, the market valuation stands at $103.62M. CHRS’s current price is a discount, trading about -173.03% off its 52-week high of $2.43. The share price had its 52-week low at $0.66, which suggests the last value was 25.84% up since then.
Analysts gave the Coherus Oncology Inc (CHRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CHRS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Coherus Oncology Inc (NASDAQ:CHRS) trade information
Instantly CHRS is in green as seen in intraday trades today. With action 16.68%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -35.23%, with the 5-day performance at 16.68% in the green. However, in the 30-day time frame, Coherus Oncology Inc (NASDAQ:CHRS) is -9.93% down.
The consensus price target for the stock as assigned by Wall Street analysts is 1.05, meaning bulls need an upside of 15.24% from its recent market value. According to analyst projections, CHRS’s forecast low is 1.05 with 1.05 as the target high. To hit the forecast high, the stock’s price needs a -17.98% plunge from its current level, while the stock would need to soar -17.98% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -27.36%. The 2025 estimates are for Coherus Oncology Inc earnings to decrease by -626.69%.
CHRS Dividends
Coherus Oncology Inc is expected to release its next quarterly earnings report in July.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.2339% or 10.6 million shares worth $18.34 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 3.43 shares estimated at $3.05 million under it, the former controlled 2.96% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.34% of the shares, roughly 2.71 shares worth around $2.4 million.
